Patents by Inventor Esteban C. Gabazza

Esteban C. Gabazza has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200291406
    Abstract: Provided is siRNA effective for the treatment of fibrosis and a pharmaceutical containing the siRNA.
    Type: Application
    Filed: August 1, 2019
    Publication date: September 17, 2020
    Applicants: MIE UNIVERSITY, Otsuka Pharmaceutical Co., Limited
    Inventors: Esteban C GABAZZA, Tetsu KOBAYASHI, Hidekazu TOYOBUKU, Ayako FUKUDA, Tetsuya HASEGAWA
  • Patent number: 10251378
    Abstract: A transgenic mouse has a genome that includes the entire gene region of human transforming growth factor beta-1 (human TGF?1) located downstream of a mouse Podocin promoter such that expression of the human TGF?1 is controlled by the mouse Podocin promoter. The human TGF?1 contains 7 exons and 6 introns, the human TGF?1 is expressed in a kidney of the mouse as non-active TGF?1 and becomes active TGF?1 extracellularly, and the transgenic mouse spontaneously develops renal fibrosis.
    Type: Grant
    Filed: June 24, 2015
    Date of Patent: April 9, 2019
    Assignee: MIE UNIVERSITY
    Inventors: Yutaka Yano, Esteban C. Gabazza, Corina Gabazza
  • Publication number: 20190010500
    Abstract: Provided is siRNA effective for the treatment of fibrosis and a pharmaceutical containing the siRNA.
    Type: Application
    Filed: September 24, 2018
    Publication date: January 10, 2019
    Applicants: MIE UNIVERSITY, Otsuka Pharmaceutical Co., Limited
    Inventors: Esteban C. Gabazza, Tetsu Kobayashi, Hidekazu Toyobuku, Ayako Fukuda, Tetsuya Hasegawa
  • Patent number: 10125366
    Abstract: Provided is siRNA effective for the treatment of fibrosis and a pharmaceutical containing the siRNA.
    Type: Grant
    Filed: March 22, 2017
    Date of Patent: November 13, 2018
    Assignees: MIE UNIVERSITY, OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Esteban C Gabazza, Tetsu Kobayashi, Hidekazu Toyobuku, Ayako Fukuda, Tetsuya Hasegawa
  • Patent number: 9894889
    Abstract: A transgenic non-human mammal has a genome that includes an early-immediate enhancer of human cytomegalovirus (CMV enhancer), a ?-actin promoter and the entire gene region of human matrix metalloproteinase 2 (hMMP2) disposed downstream of the promoter. The hMMP2 is systemically expressed in the transgenic non-human mammal, which thus provides a suitable animal model for studying chronic obstructive pulmonary disease and related diseases and conditions.
    Type: Grant
    Filed: December 10, 2014
    Date of Patent: February 20, 2018
    Assignee: MIE UNIVERSITY
    Inventors: Esteban C. Gabazza, Osamu Taguchi, Tetsu Kobayashi
  • Publication number: 20170198293
    Abstract: Provided is siRNA effective for the treatment of fibrosis and a pharmaceutical containing the siRNA.
    Type: Application
    Filed: March 22, 2017
    Publication date: July 13, 2017
    Applicants: Mie University, Otsuka Pharmaceutical Co., Ltd.
    Inventors: Esteban C. GABAZZA, Tetsu KOBAYASHI, Hidekazu TOYOBUKU, Ayako FUKUDA, Tetsuya HASEGAWA
  • Publication number: 20170135328
    Abstract: A transgenic mouse has a genome that includes the entire gene region of human transforming growth factor beta-1 (human TGF?1) located downstream of a mouse Podocin promoter such that expression of the human TGF?1 is controlled by the mouse Podocin promoter. The human TGF?1 contains 7 exons and 6 introns, the human TGF?1 is expressed in a kidney of the mouse as non-active TGF?1 and becomes active TGF?1 extracellularly, and the transgenic mouse spontaneously develops renal fibrosis.
    Type: Application
    Filed: June 24, 2015
    Publication date: May 18, 2017
    Inventors: Yutaka YANO, Esteban C. GABAZZA, Corina GABAZZA
  • Patent number: 9637743
    Abstract: Provided is siRNA effective for the treatment of fibrosis and a pharmaceutical containing the siRNA.
    Type: Grant
    Filed: January 19, 2016
    Date of Patent: May 2, 2017
    Assignees: MIE UNIVERSITY, OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Esteban C Gabazza, Tetsu Kobayashi, Hidekazu Toyobuku, Ayako Fukuda, Tetsuya Hasegawa
  • Publication number: 20160374319
    Abstract: A transgenic non-human mammal has a genome that includes an early-immediate enhancer of human cytomegalovirus (CMV enhancer), a ?-actin promoter and the entire gene region of human matrix metalloproteinase 2 (hMMP2) disposed downstream of the promoter. The hMMP2 is systemically expressed in the transgenic non-human mammal, which thus provides a suitable animal model for studying chronic obstructive pulmonary disease and related diseases and conditions.
    Type: Application
    Filed: December 10, 2014
    Publication date: December 29, 2016
    Inventors: Esteban C. Gabazza, Osamu TAGUCHI, Tetsu KOBAYASHI
  • Publication number: 20160130586
    Abstract: Provided is siRNA effective for the treatment of fibrosis and a pharmaceutical containing the siRNA.
    Type: Application
    Filed: January 19, 2016
    Publication date: May 12, 2016
    Applicants: Mie University, Otsuka Pharmaceutical Co., Ltd.
    Inventors: Esteban C. Gabazza, Tetsu Kobayashi, Hidekazu Toyobuku, Ayako Fukuda, Tetsuya Hasegawa
  • Patent number: 9273314
    Abstract: Provided is siRNA effective for the treatment of fibrosis and a pharmaceutical containing the siRNA.
    Type: Grant
    Filed: May 8, 2014
    Date of Patent: March 1, 2016
    Assignees: MIE UNIVERSITY, OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Esteban C Gabazza, Tetsu Kobayashi, Hidekazu Toyobuku, Ayako Fukuda, Tetsuya Hasegawa
  • Publication number: 20140288151
    Abstract: Provided is siRNA effective for the treatment of fibrosis and a pharmaceutical containing the siRNA.
    Type: Application
    Filed: May 8, 2014
    Publication date: September 25, 2014
    Applicants: Mie University, Otsuka Pharmaceutical Co., Ltd.
    Inventors: Esteban C GABAZZA, Tetsu Kobayashi, Hidekazu Toyobuku, Ayako Fukuda, Tetsuya Hasegawa
  • Patent number: 8772262
    Abstract: Provided is siRNA effective for the treatment of fibrosis and a pharmaceutical containing the siRNA. An siRNA having a full length of 30 or fewer nucleotides and targeting a sequence consisting of 17 to 23 consecutive bases selected from the group consisting of bases at positions 1285 to 1318, bases at positions 1398 to 1418, bases at positions 1434 to 1463, bases at positions 1548 to 1579, bases at positions 1608 to 1628, bases at positions 1700 to 1726, bases at positions 1778 to 1798, bases at positions 1806 to 1826, and bases at positions 1887 to 1907 of SEQ ID NO: 1.
    Type: Grant
    Filed: October 14, 2011
    Date of Patent: July 8, 2014
    Assignees: Mie University, Otsuka Pharmaceutical Co., Ltd.
    Inventors: Esteban C Gabazza, Tetsu Kobayashi, Hidekazu Toyobuku, Ayako Fukuda, Tetsuya Hasegawa
  • Publication number: 20130217754
    Abstract: Provided is siRNA effective for the treatment of fibrosis and a pharmaceutical containing the siRNA. An siRNA having a full length of 30 or fewer nucleotides and targeting a sequence consisting of 17 to 23 consecutive bases selected from the group consisting of bases at positions 1285 to 1318, bases at positions 1398 to 1418, bases at positions 1434 to 1463, bases at positions 1548 to 1579, bases at positions 1608 to 1628, bases at positions 1700 to 1726, bases at positions 1778 to 1798, bases at positions 1806 to 1826, and bases at positions 1887 to 1907 of SEQ ID NO: 1.
    Type: Application
    Filed: October 14, 2011
    Publication date: August 22, 2013
    Applicants: OTSUKA PHARMACEUTICAL CO., LTD., MIE UNIVERSITY
    Inventors: Esteban C. Gabazza, Tetsu Kobayashi, Hidekazu Toyobuku, Ayako Fukuda, Tetsuya Hasegawa